Acute hepatic cytolysis in an HIV-infected patient taking atazanavir

被引：8

作者：

Eholié, SP ^{[1
]}

Lacombe, K

Serfaty, L

Wendum, D

Girard, PM

机构：

[1] Hop St Antoine, Serv Malad Infect, F-75571 Paris, France

[2] Hop St Antoine, Serv Hepatol, F-75571 Paris, France

[3] Hop St Antoine, Serv Anat Pathol, F-75571 Paris, France

来源：

AIDS | 2004年 / 18卷 / 11期

关键词：

D O I：

10.1097/01.aids.0000131369.90575.9e

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

收藏

页码：1610 / 1611

页数：2

相关论文

共 8 条

[1] Arribas JR, 1998, AIDS, V12, P1722
[2] CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .2. AN ORIGINAL MODEL FOR VALIDATION OF DRUG CAUSALITY ASSESSMENT METHODS - CASE-REPORTS WITH POSITIVE RECHALLENGE
BENICHOU, C
DANAN, G
FLAHAULT, A
[J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) : 1331 - 1336
[3] Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
Carr, A
Cooper, DA
[J]. LANCET, 1997, 349 (9057) : 995 - 996
[4] *NAT I ALL INF DIS, 1996, DIV AIDS TABL GRAD S
[5] Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
Savès, M
Raffi, F
Clevenbergh, P
Marchou, B
Waldner-Combernoux, A
Morlat, P
Le Moing, V
Rivière, C
Chêne, G
Leport, C
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) : 3451 - 3455
[6] Indinavir-associated hepatitis in patients with advanced HIV infection
Vergis, E
Paterson, DL
Singh, N
[J]. INTERNATIONAL JOURNAL OF STD & AIDS, 1998, 9 (01) : 53 - 53
[7] Wang S, 2002, ANTIVIR THER, V7, pL6
[8] Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy
Wit, FWNM
Weverling, GJ
Weel, J
Jurriaans, S
Lange, JMA
[J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (01) : 23 - 31